Care choices for a joint that stays sore

What to change before a procedure

Reduce any movement that sharply raises soreness, but don't stop all activity. A shorter walk or lighter task keeps the joint moving with less strain.

Build strength slowly, because nearby muscle helps carry body weight and force. If you add too much at once, soreness may last into tomorrow.

Use heat before movement if it eases stiffness, then try cold afterward. Pain-relief gel is another choice after your doctor checks its safety.

Sleep and body weight can change the strain placed on a joint. Small, steady changes are often easier to keep than one hard push.

What to ask about non-surgical choices

Platelet-rich plasma is shortened to PRP; the clinic spins your blood so more platelets collect for a joint shot. Ask which preparation the clinic uses, because the finished shots can differ.

Other shots may start with marrow, the soft center inside bone, or fat. Ask what will be used, how the shot is given, and who gives it.

Relief has varied in human studies, so no one can promise your result. Less soreness isn't evidence that worn cartilage grew back.

Ask how long the doctor will wait before judging the result. Get the total price, visit count, and any limits during recovery.

What to do when basic care isn't enough

If basic care isn't enough, an exam can narrow the choices. A doctor may discuss more therapy, medicine, a shot, or the timing of surgery.

QC Kinetix in Chandler offers natural pain treatments such as PRP and concentrated PRP, both non-surgical shots prepared from blood. The preparations aren't the same, so ask the clinic to explain the difference.

Orthobiologics is the medical name for these blood-, marrow-, or fat-based shots. Joint preservation means care aimed at keeping the joint you have and postponing surgery.

Ask whether the offered care may ease soreness or improve quality of life. For knee or hip surgery alternatives, ask how long any relief could continue.

Sources

1. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis is the orthopedic profession's own GRADE-style appraisal of the same options a regenerative clinic sells; it is the benchmark against which any 'regenerative' claim on this topic should be read, and it rates the strongest support for exercise, weight loss and self-management rather than for injectables.

   Brophy RH, et al. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. The Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

2. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

3. A Level-1 systematic review of 8 randomized trials (937 patients) of bone marrow aspirate concentrate for knee OA found BMAC improved clinical scores versus baseline from one month, and beat hyaluronic acid on pain at 6 and 12 months with statistical significance - but those differences DID NOT EXCEED the minimal clinically important difference, and against other injections no significant difference appeared at all. Statistically detectable is not the same as noticeable.

   Han JH, et al. — Bone Marrow Aspirate Concentrate Injections for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials.. Orthopaedic journal of sports medicine, 2024. DOI: 10.1177/23259671241296555.

4. A meta-analysis of 9 Level-1 trials (671 patients) of adipose stromal vascular fraction and adipose-derived MSC injections for knee OA found SVF superior to saline or hyaluronic acid on pain and function at 3, 6 and 12 months - but INFERIOR to corticosteroid at 3 months, no different at 6, and only comparable or slightly superior at 12. Adipose-derived MSCs beat saline and conservative care but showed no significant difference versus HA. No serious adverse events were attributed to the injections themselves, though complications associated with the LIPOSUCTION step were observed.

   Han JH, et al. — Intra-articular Stromal Vascular Fraction and Mesenchymal Stem Cell Injections Show Variable Efficacy and Higher Potential Complications Compared to Corticosteroid and Hyaluronic Acid in Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials.. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2025. DOI: 10.1016/j.arthro.2025.01.050.

5. The strongest recent POSITIVE signal: a meta-analysis of 10 RCTs (818 patients, KL I-III) found intra-articular MSC injection beat hyaluronic acid at 12 months on WOMAC total (MD -10.22), VAS (MD -1.31) and on the MRI Whole-Organ Magnetic Resonance Imaging Score (MD -26.01), all reaching the minimal clinically important difference, with no significant difference in adverse events. Recorded here at full weight: this result and the negative RESTORE and Mautner trials are both in the literature, and an honest page reports both.

   Jin WS, et al. — Mesenchymal Stem Cells Injection Is More Effective Than Hyaluronic Acid Injection in the Treatment of Knee Osteoarthritis With Similar Safety: A Systematic Review and Meta-analysis.. Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2025. DOI: 10.1016/j.arthro.2024.07.027.

6. The evidence overview underpinning the 2020 EULAR recommendations on intra-articular therapies pooled 29 quality-appraised systematic reviews. Hyaluronic acid showed a small effect on pain and function in KNEE OA but not in hip OA or shoulder capsulitis; intra-articular glucocorticoid showed small effects in knee OA and on function in hip OA and shoulder capsulitis; PRP showed benefit in knee OA but NOT in hip OA, and mesenchymal stem cells behaved similarly. Overall conclusion: most intra-articular therapies exert SMALL effects and are well tolerated.

   Rodriguez-García SC, et al. — Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews.. RMD open, 2021. DOI: 10.1136/rmdopen-2021-001658.

7. The Cochrane review of platelet-rich therapies for musculoskeletal SOFT TISSUE injuries - the tendon, ligament and muscle indications regenerative clinics also market - concluded the evidence was insufficient to support their use, with small trials and inconsistent outcome reporting. It remains the reference cold-water assessment for the non-arthritis half of this field.

   Moraes VY, et al. — Platelet-rich therapies for musculoskeletal soft tissue injuries.. The Cochrane database of systematic reviews, 2014. DOI: 10.1002/14651858.CD010071.pub3.

8. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

9. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

10. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it.

    Sadeghirad B, et al. — Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.. Osteoarthritis and cartilage, 2024. DOI: 10.1016/j.joca.2024.04.021.

11. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

    Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.

12. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other.

    Eckstein F, et al. — Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.. Annals of the rheumatic diseases, 2021. DOI: 10.1136/annrheumdis-2020-219181.